0001415889-23-011882.txt : 20230804
0001415889-23-011882.hdr.sgml : 20230804
20230804193310
ACCESSION NUMBER: 0001415889-23-011882
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230802
FILED AS OF DATE: 20230804
DATE AS OF CHANGE: 20230804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coen Stacy Ann
CENTRAL INDEX KEY: 0001814150
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17999
FILM NUMBER: 231145354
MAIL ADDRESS:
STREET 1: 11 RUSH POND RD
CITY: LAKEVILLE
STATE: MA
ZIP: 02347
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunoGen, Inc.
CENTRAL INDEX KEY: 0000855654
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042726691
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781)895-0600
MAIL ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOGEN INC
DATE OF NAME CHANGE: 19920703
4
1
form4-08042023_110803.xml
X0508
4
2023-08-02
0000855654
ImmunoGen, Inc.
IMGN
0001814150
Coen Stacy Ann
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM
MA
02451
false
true
false
false
SVP & CHIEF BUSINESS OFFICER
0
Common Stock
2023-08-02
4
M
0
4255
4.92
A
15215
D
Common Stock
2023-08-02
4
S
0
4255
18.12
D
10960
D
Common Stock
2023-08-04
4
M
0
80326
4.92
A
91286
D
Common Stock
2023-08-04
4
S
0
80326
17.05
D
10960
D
Stock Option (Right to Buy)
4.92
2023-08-02
4
M
0
4255
0
D
2021-06-01
2030-06-01
Common Stock
4255
255745
D
Stock Option (Right to Buy)
4.92
2023-08-04
4
M
0
80326
0
D
2021-06-01
2030-06-01
Common Stock
80326
175419
D
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
/s/ Renee Lentini, Attorney-in-Fact
2023-08-04